ClinicalTrials.gg
CompletedNCT00171886Updated Feb 24, 2017

Octreotide Efficacy and Safety in First-line Acromegalic Patients

A Phase 4 interventional study of Octreotide in Acromegaly, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
20th of 25
20 · median 56
Started
2002
with 2 others
Phase 4
10 of 25
none open now
Registered
4th of 25
by date
Lead sponsor
5 of 25
Novartis Pharmaceuticals

Among the 25 studies testing octreotide in Acromegaly, this one is the 20th largest by enrollment, is one of 3 that started in 2002, is one of 10 in phase 4, and was the 4th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

Primary Acromegaly is a clinical and metabolic disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma and is an insidious, chronic disease that is associated with bony and soft tissue overgrowth. Goals of therapy are to eradicate the tumor, suppress GH secretion, normalize IGF-I levels, and preserve normal pituitary function.

This study will evaluate the safety and efficacy of octreotide as primary therapy for the treatment of acromegaly and as therapy for patients with acromegaly and a pituitary macroadenoma or microadenoma.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
  • Otreotide
  • Tumor reduction
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 18 and \< 80 years old.
  • Recently diagnosed not previously treated patients with acromegaly.
  • Presence of a pituitary tumor (microadenoma or macroadenoma), documented by a MNR performed in the 12 weeks before enrolment.
  • Absence of nadir suppression of the nadir of GH to \< 1.0 ng/mL, after oral administration of 75 g of glucose (OTTG).
  • IGF-I levels over normal upper limits, e.g. 97 percentile (age- and sex-matched).
  • Tolerance shown with a test of a subcutaneous injection of octreotide
  • Written before any procedure specific to the study. Inclus

Exclusion criteria

Exclusion Criteria:

  • Previously treated patients with any therapy for acromegaly, including surgery, radiotherapy, bromocriptin, and somatostatin analogues.
  • Compression of optic chiasm that produces any impairment of field of vision.
  • Need of surgery to improve any neurological sign or symptom associated with a direct incidence on the tumour.
  • Intolerance to octreotide or to any component of Sandostatin® LAR® preparation.
  • Patients with an hepatic condition such as cirrhosis, active or persisting chronic hepatitis, or other hepatopathy of fast evolution.
  • Pregnant women
  • History of alcohol or drug abuse in the six months prior to the inclusion visit.
  • Patients suffering from any condition that may jeopardize the interpretation of study results or may impede to obtain
  • Intake of an drug during the study and 30 days before patient inclusion in this study

Other protocol-defined inclusion / exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    octrotide

    Drug: Octreotide

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the ability of Sandostatin® LAR® to decrease GH and IGF-I levels in acromegaly patients with micro- or macroadenomas not previously treated

    Time frame: at baseline, weeks 12, 24, 48

  2. To evaluate efficacy of Sandostatin® LAR® to reduce the size of micro- or macroadenomas in acromegaly patients with micro- or macroadenomas not previous treated

    Time frame: at baseline, weeks 12, 24, 48

Secondary outcomes

  1. To evaluate the effect of Sandostatin® LAR® on Health Related Quality of Life.

    Time frame: at baseline, weeks 12, 24, 48

  2. To evaluate the ability of Sandostatin® LAR® to relieve acromegaly signs and symptoms

    Time frame: at baseline, weeks 12, 24, 48

07

Study locations

8 sites
  • Novartis Investigative site
    Alicante, Spain
  • Novartis Investigative site
    Barcelona, Spain
  • Novartis Investigative site
    Burgos, Spain
  • Novartis Investigative site
    Cordoba, Spain
  • Novartis Investigative site
    Coruna, Spain
  • Novartis Investigative site
    Madrid, Spain
  • Novartis Investigative site
    Malaga, Spain
  • Novartis Investigative site
    Tarragona, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 15, 2005
Start
Jul 2002
Primary completionActual
May 2006
CompletionActual
May 2006
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00171886
First posted
Sep 15, 2005
Start date
Jul 2002
Primary completion
May 2006
Completion
May 2006
Last update
Feb 24, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion